| 期 |
栏目 |
标题 |
文件 |
| 卷 9, 编号 4 (2012) |
Articles |
Diurnal blood pressure variability as a risk factor for complications of arterial hypertension |
|
| 卷 10, 编号 1 (2013) |
Articles |
Effect of the fixed-dose combination Ekvator on blood pressure level and cognitive functions in elderly patients with arterial hypertension |
|
| 卷 10, 编号 2 (2013) |
Articles |
Efficacy of irbesartan in arterial hypertension and metabolic syndrome |
|
| 卷 10, 编号 3 (2013) |
Articles |
Covremennye predstavleniya ob ideal'noy kombinatsii antigipertenzivnykh preparatov dlya profilaktiki insul'ta |
|
| 卷 11, 编号 1 (2014) |
Articles |
The value of blood pressure variability in clinical practice. Opportunities of amlodipine in reducing blood pressure variability (based on the Russian program «VARIATIONS») |
(Rus)
|
| 卷 11, 编号 1 (2014) |
Articles |
New trends in the treatment of hypertension in 2013: the renaissance of pulse pressure |
(Rus)
|
| 卷 11, 编号 2 (2014) |
Articles |
The benefits of candesartan usage in the treatment of arterial hypertension |
(Rus)
|
| 卷 11, 编号 4 (2014) |
Articles |
First results of the Russian database of international prospective observational registry variability of blood pressure in patients with hypertension |
(Rus)
|
| 卷 11, 编号 3 (2014) |
Articles |
The combination therapy in arterial hypertension: opportunities of the fixed combination of irbesartan andhydrochlorothiazide(Koaprovel’) |
(Rus)
|
| 卷 12, 编号 2 (2015) |
Articles |
The hardness of the vessel wall in patients with arterial hypertension |
(Rus)
|
| 卷 12, 编号 1 (2015) |
Articles |
The association of arterial hypertension and ischemic heart disease is the main problem in modern cardiology practice |
(Rus)
|
| 卷 12, 编号 4 (2015) |
Articles |
From the choice of antihypertensive drug to the choice of fixed combinations of antihypertensive drugs: a paradigm shift |
(Rus)
|
| 卷 13, 编号 1 (2016) |
Articles |
The role of b-blockers in treatment of hypertension, according to Russian and European experts |
(Rus)
|
| 卷 12, 编号 4 (2015) |
Articles |
A modern view of the place of b-blockers in the treatmentof cardiovascular disease: the choice of drug within a class is crucial |
(Rus)
|
| 卷 14, 编号 4 (2017) |
Articles |
Markers of early target-organ brain damage in essential arterial hypertension: the search continues. Possibilities of diffusion tensor magnetic resonance imaging |
(Rus)
|
| 卷 14, 编号 3 (2017) |
Articles |
The efficacy and safety of torasemid in the treatment of arterial hypertension in different clinical situations |
(Rus)
|
| 卷 15, 编号 1 (2018) |
Articles |
Fixed combination of amlodipine and lisinopril effectiveness in hypertensive smokers |
(Rus)
|
| 卷 15, 编号 2 (2018) |
Articles |
The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 grades in international VICTORY clinical trial |
(Rus)
|
| 卷 15, 编号 2 (2018) |
Articles |
Stroke prevention in patients with atrial fibrillation and comorbidities |
(Rus)
|
| 卷 15, 编号 4 (2018) |
Articles |
The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities |
(Rus)
|
| 卷 6, 编号 4 (2009) |
Articles |
Fleita is a Russian randomized, open-label, multicenter, comparative program for the evaluation of the efficacy and safety of the fixed combination drug Tarka (ABBOTT Laboratories, USA) versus optional sustained-release antihypertensive drugs in the treatment of patients with arterial hypertension and cognitive disorders (stepwise strategy) |
|
| 卷 6, 编号 4 (2009) |
Articles |
Arterial hypertension in the elderly and higher mental functions. Possibilities of an-tihypertensive therapy withArifon retard in the prevention of dementia. |
|
| 卷 16, 编号 3 (2019) |
Articles |
Target levels of blood pressure in the elderly and very old patients with chronic kidney disease without frailty |
(Rus)
|
| 卷 16, 编号 2 (2019) |
Articles |
Drug-induced arterial hypertension |
(Rus)
|
| 卷 16, 编号 4 (2019) |
Articles |
Target blood pressure levels in patients with arterial hypertension and frailty |
(Rus)
|
| 卷 17, 编号 1 (2020) |
Review |
Evidence base regarding target levels of arterial pressure in patients after a stroke: focus on a geriatric population |
(Rus)
|
| 卷 17, 编号 2 (2020) |
Original Article |
First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension |
(Rus)
|
| 卷 17, 编号 2 (2020) |
Review |
COVID-19: a patient with cardiovascular disease at high risk |
(Rus)
|
| 卷 17, 编号 3 (2020) |
Articles |
Implementation of the organoprotective properties of fixed combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with grade 2 and 3 hypertension in the Russian clinical study VICTORY II |
(Rus)
|
| 卷 17, 编号 3 (2020) |
Expert opinion |
Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19 |
(Rus)
|
| 卷 18, 编号 1 (2021) |
Expert opinion |
Expert consensus. Effect of antihypertensive therapy on cognitive functions |
(Rus)
|
| 卷 18, 编号 1 (2021) |
Original Article |
Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II |
(Rus)
|
